Brielle Benyon

An artificial-intelligence based tool helped patients find and understand clinical trials, which could eventually lead to more diverse trial populations.

The FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with locally advanced or metastatic HER2-postive gastric or gastroesophageal (GEJ) adenocarcinoma who previously received a trastuzumab-based regimen.

It's not time to throw away the masks just yet.

We spoke with researchers on the factors that led to nurse loneliness – and what can be done to help.

Nurses should be careful of the words that they choose – around patients and other providers.

Nurse navigation – in addition to a better EHR system – increased the percentage of older patients who utilized advance care planning.

An immunotherapy agent recently had its FDA approval pulled from the American market. But this may not be as bad as it sounds, experts say.

Recent research found that there may be a correlation between opioid use and pancreatic cancer risk.

There is still more to be done in the fields of targeted therapy and immunotherapy, according to the American Cancer Society.

Results of confirmatory trials showed that the drug did not meet its primary endpoints for patients with small cell lung cancer.

Regulating the fas protein may be the key in overcoming resistance in patients receiving immunotherapy treatment, such as CAR T-cell therapy.

Only 4 of the 20 most common cancers have a proven screening method.

While there are multiple ways to create and deliver a survivorship care plan, clinicians should be thinking about these issues from the moment a patient is diagnosed.

This is the second COVID-19 vaccine to be granted Emergency Use Authorization by the FDA.

The FDA approved selinexor (Xpovio) plus bortezomib and dexamethasone for the treatment of patients with myeloma who previously had at least 1 other treatment.

Nurses want to be seen as leaders in their field, but their image in the public and in the media does not convey that yet. Two experts discuss how to change the “branding” of the profession.

Oncology nurse practitioners are both competent and compassionate, and undergo rigorous academic and clinical training to earn the NP next to their name. However, many states still require them to work under the supervision of a physician.

Four oncology nurse practitioners sat down and discussed the recent developments in the treatment of HER2-positive breast cancer and how to manage this group of patients during a worldwide pandemic.

Oncology nurses do not realize how appreciated they truly are. See the heartfelt thanks that patients shared.

The FDA issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of SARS-CoV-2 (which causes the coronavirus) for people aged 16 years or older.

BNT162b2 is the first vaccine recommended in the United States for the prevention of COVID-19.

Patients who experienced breakthrough CINV in their first chemotherapy cycle were more likely to have the adverse event in later cycles too, recent research found.

Patients with cancer may be more susceptible to COVID-19. As oncology nurses await the approval of a vaccine, they shared their thoughts with Oncology Nursing News.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

A recent study analyzed nurse and patient preference when it came to the administration of rituximab in patients with blood cancer.

Nurse stress can have trickle-down effects in the cancer setting, but certain interventions can help.

Recent research found 4 common occurrences that can delay chemotherapy treatment in an outpatient setting.

What was the most noteworthy news in the oncology nursing arena this year? Take our survey and tell us what you think.

The FDA approved pralsetinib (Gavreto) for adults and children aged 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who need systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory.

The FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11), a drug for PET imaging of prostate-specific membrane antigen (PSMA) positive levels in men with suspected prostate cancer metastasis, who may be curable by surgery or radiation therapy.